Previous Close | 37.85 |
Open | 38.04 |
Bid | 33.11 x 800 |
Ask | 39.27 x 900 |
Day's Range | 36.69 - 38.92 |
52 Week Range | 25.04 - 44.42 |
Volume | |
Avg. Volume | 1,093,550 |
Market Cap | 5.22B |
Beta (5Y Monthly) | 0.77 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.03 |
Earnings Date | Aug 02, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 47.33 |
A look at the shareholders of Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) can tell us which group is most powerful...
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
The FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.